Center for Biologic Counterterrorism and Emerging Diseases

ATTENZIONE!
Il tuo browser non supporta JavaScript!
Questo impedisce il corretto funzionamento delle pagine del sito.

Torna a visitarci dopo aver installato un browser più aggiornato,
come gli ultimi Microsoft Internet Explorer o Netscape Navigator.

Assicurati inoltre di aver abilitato nelle preferenze l'uso di JavaScript.

Center for Biologic Counterterrorism
and Emerging Diseases CBC-ED

MedStar Health Group Washington, DC Cloud Updated Monday, May 20, 2013 23:15 EST

Craig Feied, MD, FACEP, FAAEM Jon Handler, MD, FACEP Michael Gillam, MD

Switch to framed viewer

Logged in as: guest ()

Anthrax
	CHALLENGES IN THE USE OF ANTHRAX VACCINE ADSORBED (AVA) IN THE PEDIATRIC POPULATION AS A COMPONENT OF POST-EXPOSURE PROPHYLAXIS (PEP) A REPORT OF THE NATIONAL BIODEFENSE SCIENCE BOARD October 2011 (pdf) [10/28/2011]
	Community Storage of Anthrax-Preventing Antibiotics Should Be Determined by State, Local Agencies on Basis of Risk Level and Dispensing Capabilities, Says New Report National-Academies [10/1/2011]
	Novel Anthrax Vaccine And Antitoxin Being Developed With Federal Support HHS [9/15/2011]
	Use of Anthrax Vaccine in the United States (pdf) Recommendations of the Advisory Committee on Immunization Practices (ACIP) [3/11/2011]
	Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine [3/11/2011]
	Development Of A Highly Efficacious Vaccinia Based Dual Vaccine Against Smallpox And Anthrax, Two Important Bioterror Entities PNAS [10/25/2010]
	Biologists Use Fruit Flies To Reveal Secrets Of How Anthrax Kills UC San Diego study [10/14/2010]
	Historical Distribution and Molecular Diversity of Bacillus anthracis, Kazakhstan May 2010: EID [5/11/2010]
	Single Host Gene May Hold Key To Treating Both Ebola And Anthrax Infections Single host gene may hold key to treating both ebola and anthrax infections [8/22/2009]
	CDC Anthrax Q & A Preventive Therapy CDC Anthrax Q & A: Preventive Therapy [5/8/2009]
	Public Health And Clinical Guidelines For Anthrax CDC EID [3/28/2009]

Anthrax Bepast Newsletters
	N-95 Respirator fit-testing required for US postal carriers to receive a "Household Antibiotic Kit" (doxycycline) for use during an Anthrax attack [10/20/2008]
	22 U.S. contracts for “Covered Countermeasures” against anthrax listed in HHS PREP Act Declaration [10/4/2008]
	US to make antibiotics available for postal workers and household members as CRI preparedness for anthrax [10/3/2008]
	Unsubstantiated terror alert for US hospitals: anthrax or explosives November 14, 2002: Daniel R. Lucey, MD, MPH, Center for Biologic Counterterrorism and Emerging Diseases [1/1/2007]
	Anthrax Antitoxin Antibody: Second Source to be Added to Stockpile July 26, 2006: Daniel R. Lucey, MD, MPH, Center for Biologic Counterterrorism and Emerging Diseases [1/1/2007]
	Additives or Not: The Anthrax Mailed in October 2001 Could Form an Aerosol and Could Reaerosolize October 17 2001: Daniel R. Lucey, MD, MPH, Center for Biologic Counterterrorism and Emerging Diseases [1/1/2007]
	Drainage of pleural fluid in patients with inhalational anthrax: a critical need to be anticipated as part of combination therapy May 24, 2005: Daniel R. Lucey, MD, MPH, Center for Biologic Counterterrorism and Emerging Diseases [5/23/2005]
	Anthrax: Key Reminders and Updates for Clinicians March 17, 2005: Daniel R. Lucey, MD, MPH, Center for Biologic Counterterrorism and Emerging Diseases [3/16/2005]
	A New Staging System for Inhalational Anthrax: Rewriting the Textbooks January 24, 2005: Daniel R. Lucey, MD, MPH, Center for Biologic Counterterrorism and Emerging Diseases [1/23/2005]
	Anthrax Vaccine After Exposure to Aerosolized Anthrax Spores September 14, 2004: Daniel R. Lucey, MD, MPH, Center for Biologic Counterterrorism and Emerging Diseases [11/13/2004]
	Anthrax-Specific Intravenous Hyperimmune Globulin November 28, 2002: Daniel R. Lucey, MD, MPH, Center for Biologic Counterterrorism and Emerging Diseases [11/27/2002]

Anthrax Disease Information
	Q & A on Anthrax Vaccine [2/11/2009]
	Medical Progress: Anthrax New England Journal of Medicine, September 9, 1999 [2/11/2009]
	Mortality Of Anthrax Attack A mathematical model suggests a single anthrax attack could cost more than 100,000 lives. Proceedings of the National Academy of Science, 2003, as reported by Reuters Health [2/11/2009]
	CDC:Anthrax of the Gastrointestinal Tract From Emerging Infectious Diseases, Thira Sirisanthana and Arthur E. Brown, Chiang Mai University, Chiang Mai, Thailand; and Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand [2/11/2009]
	CDC: Adverse Events From Anthrax Prophylaxis Update: Adverse Events Associated with Anthrax Prophylaxis Among Postal Employees – New Jersey, New York City, and the District of Columbia Metropolitan Area, 2001 [2/11/2009]
	Anthrax protocols at Washington Hospital Center Anthrax protocols being followed at WHC in Washington, DC, where many exposed or potentially exposed patients have sought treatment [2/11/2009]
	Anthrax Vaccine Makeover Science News [10/4/2008]
	Effects Of A Reduced Dose Schedule And Intramuscular Administration Of Anthrax Vaccine Adsorbed on Immunogennicity and Safety at 7 Months JAMA Abstract [9/30/2008]
	Anthrax Toxins Inhibit Neutrophil Signaling Pathways In Brain Endothelium And Contribute To The Pathogenesis Of Meningitis PLoS ONE article [9/5/2008]
	Anthrax Pediatric Levofloxacin Prophylaxis (pdf) [5/21/2008]
	Anthrax Fact Sheet UPMC-Center for Biosecurity [1/7/2008]
	Recognition And Management Of Anthrax — An Update NEJM [1/5/2008]
	Potent Antitumor Activity Of A Urokinase Activated Engineered Anthrax Toxin PNAC Shihui Liu, Hannah Aaronson, David J. Mitola, Stephen H. Leppla, and Thomas H. Bugge [1/5/2008]
	Anthrax Emedicine article [1/5/2008]
	Anthrax Lethal Toxin-Mediated Killing of Human and Murine Dendritic Cells Impairs the Adaptive Immune Response October 2005: Abdelkrim Alileche, Evan R Serfass, Stefan M Muehlbauer, Steven A Porcelli, and Jürgen Brojatsch [8/11/2003]

[This site developed and operated by Craig Feied MD, Jon Handler MD, and Mike Gillam MD]